ciprofloxacin has been researched along with Opportunistic Infections in 43 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Opportunistic Infections: An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of the current study was to evaluate the safety and efficacy of ciprofloxacin for the prevention of BK viremia in kidney transplant recipients." | 9.30 | Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial. ( Gaber, AO; Graviss, EA; Knight, RJ; Kuten, SA; Moore, LW; Musick, WL; Nguyen, DT; Patel, SJ, 2019) |
| "In 31 adult patients with cystic fibrosis (CF) who were chronically infected with Pseudomonas aeruginosa we examined the effect of giving regular three monthly oral ciprofloxacin." | 9.07 | Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. ( Assoufi, BK; Hodson, ME; Sheldon, CD, 1993) |
| "The current results suggest that fluoroquinolone prophylaxis for patients with febrile neutropenia may be abandoned safely in areas with a high prevalence of ciprofloxacin-resistant enterobacteria." | 7.72 | Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. ( Dalmau, D; Estany, C; Estrada, C; Garau, J; Gomez, L; Marquez, M; Martí, JM; Xercavins, M, 2003) |
| "Unfortunately, neutropenia is common." | 5.31 | The efficacy of prophylactic outpatient antibiotics for the prevention of neutropenic fever associated with high-dose etoposide (VP-16) for stem cell mobilization. ( Andresen, SW; Avery, RK; Bernhard, L; Bolwell, BJ; Goormastic, M; Kalaycio, ME; Kuczkowski, E; Longworth, DL; Mossad, SB; Ostendorf, H; Pohlman, BL; Sobecks, RM; Wise, K, 2002) |
| " The purpose of the current study was to evaluate the safety and efficacy of ciprofloxacin for the prevention of BK viremia in kidney transplant recipients." | 5.30 | Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial. ( Gaber, AO; Graviss, EA; Knight, RJ; Kuten, SA; Moore, LW; Musick, WL; Nguyen, DT; Patel, SJ, 2019) |
| "To determine whether ciprofloxacin-piperacillin is equivalent to tobramycin-piperacillin as empirical therapy for neutropenic fever." | 5.10 | Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial. ( Cushing, DA; Donowitz, GR; Harman, CP; Haverstock, DC; Herrington, DA; Hurd, DD; Kowalsky, SF; Lazarus, HM; Peacock, JE; Reed, MD; Sinclair, JW; Wade, JC, 2002) |
| "In 31 adult patients with cystic fibrosis (CF) who were chronically infected with Pseudomonas aeruginosa we examined the effect of giving regular three monthly oral ciprofloxacin." | 5.07 | Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. ( Assoufi, BK; Hodson, ME; Sheldon, CD, 1993) |
| "The current results suggest that fluoroquinolone prophylaxis for patients with febrile neutropenia may be abandoned safely in areas with a high prevalence of ciprofloxacin-resistant enterobacteria." | 3.72 | Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. ( Dalmau, D; Estany, C; Estrada, C; Garau, J; Gomez, L; Marquez, M; Martí, JM; Xercavins, M, 2003) |
| "aeruginosa isolates from children with hematologic malignancies containing bacterial persisters that cause the AT phenomenon." | 2.82 | [Generation of Antibiotic Tolerant Bacterial Persisters in Immunocompromized Patients with Hematologic and Malignant Diseases: A New Problem of Health-Care Associated Infections]. ( Gaponov, AM; Gracheva, AN; Minaeva, NZ; Pisarev, VM; Solopova, GG; Tutelyan, AV, 2016) |
| "Periodontitis is associated with microflorae which may consist of indigenous, exogenous or superinfecting organisms." | 2.38 | Antimicrobial therapy in periodontics. ( Slots, J; van Winkelhoff, AJ, 1993) |
| "A patient with chronic lymphocytic leukemia developed a cutaneous infection with the clinical pattern of necrotizing otitis externa." | 1.32 | [Necrotizing otitis externa caused by Stenotrophomonas maltophilia]. ( Börner, D; Fischer, M; Marsch, WC, 2003) |
| "Unfortunately, neutropenia is common." | 1.31 | The efficacy of prophylactic outpatient antibiotics for the prevention of neutropenic fever associated with high-dose etoposide (VP-16) for stem cell mobilization. ( Andresen, SW; Avery, RK; Bernhard, L; Bolwell, BJ; Goormastic, M; Kalaycio, ME; Kuczkowski, E; Longworth, DL; Mossad, SB; Ostendorf, H; Pohlman, BL; Sobecks, RM; Wise, K, 2002) |
| "We report a case of Candida purulent constrictive pericarditis in an immunocompromised heart transplant patient who was treated successfully with antifungal agents, surgical drainage, and pericardiectomy." | 1.30 | Fungal purulent constrictive pericarditis in a heart transplant patient. ( Canver, CC; Kosolcharoen, P; Patel, AK; Voytovich, MC, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.98) | 18.7374 |
| 1990's | 14 (32.56) | 18.2507 |
| 2000's | 19 (44.19) | 29.6817 |
| 2010's | 6 (13.95) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Shilabin, AG | 1 |
| Kasanah, N | 1 |
| Wedge, DE | 1 |
| Hamann, MT | 1 |
| Baldovino Chiquillo, L | 1 |
| Rico, DL | 1 |
| Leal, DD | 1 |
| Romero, M | 1 |
| Tutelyan, AV | 1 |
| Pisarev, VM | 1 |
| Minaeva, NZ | 1 |
| Gaponov, AM | 1 |
| Gracheva, AN | 1 |
| Solopova, GG | 1 |
| Patel, SJ | 1 |
| Knight, RJ | 1 |
| Kuten, SA | 1 |
| Graviss, EA | 1 |
| Nguyen, DT | 1 |
| Moore, LW | 1 |
| Musick, WL | 1 |
| Gaber, AO | 1 |
| Josa Laorden, C | 1 |
| Gómez del Valle, C | 1 |
| Bucar Barjud, M | 1 |
| Amores Arriaga, MB | 1 |
| Torralba Cabeza, MA | 1 |
| Pérez Calvo, JI | 1 |
| Baluch, A | 1 |
| Pasikhova, Y | 1 |
| Snyder, M | 1 |
| Friedl, C | 1 |
| Hackl, G | 1 |
| Schilcher, G | 1 |
| Rosenkranz, AR | 1 |
| Eller, K | 1 |
| Eller, P | 1 |
| Skindersoe, ME | 1 |
| Alhede, M | 1 |
| Phipps, R | 1 |
| Yang, L | 1 |
| Jensen, PO | 1 |
| Rasmussen, TB | 1 |
| Bjarnsholt, T | 1 |
| Tolker-Nielsen, T | 1 |
| Høiby, N | 2 |
| Givskov, M | 1 |
| Wong, A | 1 |
| Rodrigue, N | 1 |
| Kassen, R | 1 |
| Peacock, JE | 1 |
| Herrington, DA | 1 |
| Wade, JC | 1 |
| Lazarus, HM | 1 |
| Reed, MD | 1 |
| Sinclair, JW | 1 |
| Haverstock, DC | 1 |
| Kowalsky, SF | 1 |
| Hurd, DD | 1 |
| Cushing, DA | 1 |
| Harman, CP | 1 |
| Donowitz, GR | 1 |
| Oren, I | 1 |
| Zuckerman, T | 1 |
| Avivi, I | 1 |
| Finkelstein, R | 1 |
| Yigla, M | 1 |
| Rowe, JM | 1 |
| Avery, RK | 1 |
| Pohlman, BL | 1 |
| Mossad, SB | 1 |
| Goormastic, M | 1 |
| Longworth, DL | 1 |
| Kalaycio, ME | 1 |
| Sobecks, RM | 1 |
| Andresen, SW | 1 |
| Kuczkowski, E | 1 |
| Bernhard, L | 1 |
| Ostendorf, H | 1 |
| Wise, K | 1 |
| Bolwell, BJ | 1 |
| Gomez, L | 1 |
| Garau, J | 1 |
| Estrada, C | 1 |
| Marquez, M | 1 |
| Dalmau, D | 1 |
| Xercavins, M | 1 |
| Martí, JM | 1 |
| Estany, C | 1 |
| Bodey, GP | 1 |
| Rolston, KV | 1 |
| Raad, II | 1 |
| Linkin, DR | 1 |
| Fishman, N | 1 |
| Börner, D | 1 |
| Marsch, WC | 1 |
| Fischer, M | 1 |
| Otağ, F | 1 |
| Ersöz, G | 1 |
| Salcioğlu, M | 1 |
| Bal, C | 1 |
| Schneider, I | 1 |
| Bauernfeind, A | 1 |
| Roveta, S | 1 |
| Schito, AM | 1 |
| Marchese, A | 1 |
| Schito, GC | 1 |
| Jenkins, PA | 1 |
| Campbell, IA | 1 |
| Banks, J | 1 |
| Gelder, CM | 1 |
| Prescott, RJ | 1 |
| Smith, AP | 1 |
| Moser, G | 1 |
| Prammer, W | 1 |
| Wallner, M | 1 |
| Eckmayr, A | 1 |
| Bein, T | 1 |
| Ehret, W | 1 |
| Metz, C | 1 |
| Hobbhahn, J | 1 |
| Taeger, K | 1 |
| Singh, N | 1 |
| Muder, RR | 1 |
| Yu, VL | 1 |
| Gayowski, T | 1 |
| Sheldon, CD | 1 |
| Assoufi, BK | 1 |
| Hodson, ME | 1 |
| Mirelis, B | 1 |
| Miro, E | 1 |
| Navarro, F | 1 |
| Ogalla, CA | 1 |
| Bonal, J | 1 |
| Prats, G | 1 |
| Slots, J | 1 |
| van Winkelhoff, AJ | 1 |
| Gerbes, AL | 1 |
| Canver, CC | 1 |
| Patel, AK | 1 |
| Kosolcharoen, P | 1 |
| Voytovich, MC | 1 |
| Marie, JP | 1 |
| Vekhoff, A | 1 |
| Pico, JL | 1 |
| Guy, H | 1 |
| Andremont, A | 1 |
| Richet, H | 1 |
| McElvanney, AM | 1 |
| Trenschel, R | 1 |
| Peceny, R | 1 |
| Runde, V | 1 |
| Elmaagacli, A | 1 |
| Dermoumi, H | 1 |
| Heintschel von Heinegg, E | 1 |
| Müller, KD | 1 |
| Schaefer, UW | 1 |
| Beelen, DW | 1 |
| Zargar, AH | 1 |
| Masoodi, SR | 1 |
| Laway, BA | 1 |
| Wani, AI | 1 |
| Bashir, MI | 1 |
| Tabin, G | 1 |
| Danenhower, C | 1 |
| Reardon, D | 1 |
| Dimmig, J | 1 |
| McCormick, G | 1 |
| Valero, E | 1 |
| Sevillano, D | 1 |
| Calvo, A | 1 |
| García, R | 1 |
| Leturia, A | 1 |
| Gómez-Lus, ML | 1 |
| Biechy, M | 1 |
| Gálvez, E | 1 |
| Salgueró, E | 1 |
| Báñez, F | 1 |
| Romanchuk, LA | 1 |
| Bush, V | 1 |
| Korshunov, VM | 1 |
| Nelson, MR | 1 |
| Shanson, DC | 1 |
| Hawkins, D | 1 |
| Gazzard, BG | 1 |
| Piccolomini, R | 1 |
| Di Girolamo, A | 1 |
| Iacone, A | 1 |
| Fioritoni, G | 1 |
| Cellini, L | 1 |
| Nicoletti, M | 1 |
| D'Antonio, D | 1 |
| Díaz-Tejeiro, R | 1 |
| Díez, J | 1 |
| Maduell, F | 1 |
| Esparza, N | 1 |
| Errasti, P | 1 |
| Purroy, A | 1 |
| Liao, WC | 1 |
| Cappell, MS | 1 |
| Wood, ME | 1 |
| Newland, AC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ciprofloxacin for Prevention of BK Infection in Renal Transplant Recipients[NCT01789203] | Phase 4 | 200 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi[NCT01298336] | Phase 3 | 92 participants (Actual) | Interventional | 2011-03-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with biopsy-proven acute rejection of the allograft at 1 year, based on Banff classification (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 14 |
| Placebo | 7 |
Proportion of patients developing BK viremia at 1 year (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 31 |
| Placebo | 8 |
Clostridium difficile infection at 6 months (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 1 |
| Placebo | 0 |
Patient death at 1 year (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 1 |
| Placebo | 1 |
First BK plasma viral loads (NCT01789203)
Timeframe: 12 months
| Intervention | copies/mL (Median) |
|---|---|
| Ciprofloxacin | 2514 |
| Placebo | 1423 |
kidney failure within first 1 year of transplant (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 14 |
| Placebo | 7 |
Number of patients (followed by proportion) developing BK infection at 6 months post-transplant. BK infection is defined as the presence of a detectable BK viral load in plasma by polymerase chain reaction (PCR), or the presence of BK viral inclusions on kidney biopsy specimens. (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 25 |
| Placebo | 5 |
Number of patients with bacteremic infection at 6 months. Bacteremia defined by a single positive blood culture that was not thought to be contaminated. (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 3 |
| Placebo | 2 |
Number of patients with gram negative urinary tract infections as defined by a midstream urine sample containing 10^4 or more colony-forming units per mL (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 17 |
| Placebo | 14 |
Number of patients with quinolone-resistant gram negative bacterial infections, among those with a gram-negative infection (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 15 |
| Placebo | 7 |
Serious adverse events collected for up to 4 months (3 months on study drug plus 1 additional month) (NCT01789203)
Timeframe: 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 35 |
| Placebo | 18 |
Median time to initial BK viremia episode, days (NCT01789203)
Timeframe: 12 months
| Intervention | days (Median) |
|---|---|
| Ciprofloxacin | 90 |
| Placebo | 76.5 |
3 reviews available for ciprofloxacin and Opportunistic Infections
| Article | Year |
|---|---|
Waterhouse-Friderichsen syndrome due to Neisseria meningitidis infection in a young adult with thrombotic microangiopathy and eculizumab treatment: case report and review of management.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Ciprofloxacin; | 2017 |
Cystic fibrosis and endobronchial pseudomonas infection.
Topics: Bronchial Diseases; Burkholderia cepacia; Child; Ciprofloxacin; Cystic Fibrosis; Humans; Lung Transp | 1993 |
Antimicrobial therapy in periodontics.
Topics: Amoxicillin; Anti-Bacterial Agents; Ciprofloxacin; Clinical Protocols; Dental Prophylaxis; Drug Deli | 1993 |
10 trials available for ciprofloxacin and Opportunistic Infections
| Article | Year |
|---|---|
[Generation of Antibiotic Tolerant Bacterial Persisters in Immunocompromized Patients with Hematologic and Malignant Diseases: A New Problem of Health-Care Associated Infections].
Topics: Adolescent; Anti-Bacterial Agents; Child; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial | 2016 |
Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial.
Topics: Adult; BK Virus; Ciprofloxacin; Double-Blind Method; Female; Fluoroquinolones; Humans; Immunosuppres | 2019 |
Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bone Marrow Transplant | 2002 |
Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Ciprofloxacin; Clarithromycin | 2008 |
Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa.
Topics: Administration, Oral; Adult; Chronic Disease; Ciprofloxacin; Cystic Fibrosis; Double-Blind Method; D | 1993 |
[Antibiotic prophylaxis after gastrointestinal hemorrhage in liver cirrhosis--for which patients, with what antibiotics?].
Topics: Amoxicillin-Potassium Clavulanate Combination; Antibiotic Prophylaxis; Bacterial Infections; Ciprofl | 1997 |
Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Therapy, Combinati | 1998 |
Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; | 2000 |
Clinical efficacy and in vitro activity of the ciprofloxacin-azlocillin combination (ratio 1:10) against gram-negative bacteria from non-neutropenic haematologic patients.
Topics: Adult; Aged; Azlocillin; Ciprofloxacin; Drug Therapy, Combination; Female; Gram-Negative Bacteria; G | 1991 |
Intravenous ciprofloxacin in the treatment of infection in immunocompromised patients.
Topics: Adolescent; Adult; Bacterial Infections; Ciprofloxacin; Drug Therapy, Combination; Humans; Immune To | 1986 |
30 other studies available for ciprofloxacin and Opportunistic Infections
| Article | Year |
|---|---|
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
Topics: Antifungal Agents; Antineoplastic Agents; Antiparasitic Agents; Cell Line, Tumor; Depsipeptides; Dru | 2007 |
Haemophagocytic syndrome caused by disseminated nontuberculous mycobacterial infection.
Topics: Amikacin; Ciprofloxacin; Female; Humans; Lymphohistiocytosis, Hemophagocytic; Mycobacterium Infectio | 2023 |
Septic shock due to Rhodococcus equi in a patient with chronic myelomonocytic leukemia.
Topics: Actinomycetales Infections; Aged; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Diagnosis, Diffe | 2013 |
Successful management of Mycobacterium haemophilum lower extremity cutaneous infection in a matched-unrelated donor stem cell transplant recipient.
Topics: Anti-Bacterial Agents; Biopsy; Cellulitis; Ciprofloxacin; Clarithromycin; Female; Graft vs Host Dise | 2017 |
Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azithromycin; Base Sequence; Ceftazidime; Ciprofloxacin; DNA Primers; DNA, Ba | 2008 |
Genomics of adaptation during experimental evolution of the opportunistic pathogen Pseudomonas aeruginosa.
Topics: Adaptation, Biological; Cell Culture Techniques; Ciprofloxacin; Cystic Fibrosis; Directed Molecular | 2012 |
Summaries for patients. Treatment of fever in hospitalized patients with low white blood cell counts.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bone Marrow Transplant | 2002 |
Nosocomial outbreak of Legionella pneumophila serogroup 3 pneumonia in a new bone marrow transplant unit: evaluation, treatment and control.
Topics: Adult; Bone Marrow Transplantation; Ciprofloxacin; Cross Infection; Decontamination; Disease Outbrea | 2002 |
The efficacy of prophylactic outpatient antibiotics for the prevention of neutropenic fever associated with high-dose etoposide (VP-16) for stem cell mobilization.
Topics: Ambulatory Care; Antibiotic Prophylaxis; Cefepime; Cephalosporins; Ciprofloxacin; Clarithromycin; Da | 2002 |
Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremia; Ciprofloxacin | 2003 |
Ciprofloxacin versus tobramycin for neutropenic fevers.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Fever; Human | 2003 |
Ciprofloxacin versus tobramycin for neutropenic fevers.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Fever; Human | 2003 |
[Necrotizing otitis externa caused by Stenotrophomonas maltophilia].
Topics: Anti-Infective Agents; Bacteriological Techniques; Biopsy; Ciprofloxacin; Cross Infection; Dose-Resp | 2003 |
Nosocomial bloodstream infections with Burkholderia stabilis.
Topics: Adolescent; Adult; Aged; Bacteremia; Bacterial Typing Techniques; Burkholderia; Burkholderia Infecti | 2005 |
[Bacterial infections in cancer patients].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteria | 2005 |
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, B | 2005 |
[Suppurative parotitis as a sequela of infection with Salmonella enteritidis].
Topics: Abscess; Administration, Oral; Aged; Anti-Infective Agents; Ciprofloxacin; Humans; Male; Opportunist | 1995 |
[Severe legionellosis after abuse of anti-inflammatory drugs--diagnostic and intensive care aspects based on a case report].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bone Marrow; Ciprofloxacin; Combined Modality Therapy; Crit | 1995 |
Legionella infection in liver transplant recipients: implications for management.
Topics: Adult; Ciprofloxacin; Diabetic Nephropathies; Drug Therapy, Combination; Erythromycin; Female; Hepat | 1993 |
Increased resistance to quinolone in Catalonia, Spain.
Topics: Anti-Infective Agents; Campylobacter Infections; Ciprofloxacin; Drug Resistance, Microbial; Enteroba | 1993 |
Fungal purulent constrictive pericarditis in a heart transplant patient.
Topics: Amphotericin B; Anti-Infective Agents; Antifungal Agents; Candidiasis; Ciprofloxacin; Disease Suscep | 1998 |
Hypopyon keratitis in corneal epithelial basement membrane dystrophy.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Basement Membrane; Ciprofloxacin; Corneal Diseas | 1999 |
Ciprofloxacin in the management of soft tissue infections in diabetes mellitus.
Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type | 2000 |
Opportunistic Roseomonas keratitis.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Eye Infections, Bacterial; Female; Gr | 2001 |
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Ampicillin; Anti-Infective Agents; Aza Compounds; Cefepime; | 2001 |
[Soft-tissue abscess caused by Rhodococcus equi in a patient on hemodialysis].
Topics: Abscess; Actinomycetales Infections; Adrenal Cortex Hormones; Aged; Amikacin; Anti-Glomerular Baseme | 2001 |
[Selective decontamination of the intestine and total gnotobiologic isolation in treatment of mice with acute radiation sickness].
Topics: Acute Disease; Amikacin; Animals; Ciprofloxacin; Decontamination; Germ-Free Life; Intestines; Mice; | 1992 |
Shigella in HIV infection.
Topics: Adult; Ciprofloxacin; Dysentery, Bacillary; Feces; HIV Infections; Humans; Male; Opportunistic Infec | 1991 |
Successful treatment with ciprofloxacin of multiresistant salmonella arthritis in a renal transplant recipient.
Topics: Arthritis, Infectious; Ciprofloxacin; Drug Resistance, Microbial; Female; Hip Joint; Humans; Opportu | 1989 |
Treatment with ciprofloxacin of Aeromonas hydrophila associated colitis in a male with antibodies to the human immunodeficiency virus.
Topics: Adult; Aeromonas; Bacterial Infections; Ciprofloxacin; Colitis; HIV Seropositivity; Humans; Male; Op | 1989 |